U.S. flag An official website of the United States government

U.S. Food and Drug Administration
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. Guidance for Industry: Compliance Policy for Cosmetic Product Facility Registration and Cosmetic Product Listing
  1. Search for FDA Guidance Documents

GUIDANCE DOCUMENT

Guidance for Industry: Compliance Policy for Cosmetic Product Facility Registration and Cosmetic Product Listing November 2023

Download the Final Guidance Document Read the Federal Register Notice
Final
Docket Number:
FDA-2023-D-1716
Issued by:
Guidance Issuing Office
Office of the Commissioner, Office of the Chief Scientist

This guidance is intended to assist owners or operators of cosmetic product facilities that are subject to the requirements related to facility registration and responsible persons that are subject to the requirements related to cosmetic product listing under the Federal Food, Drug, and Cosmetic Act (FD&C Act). This guidance document discusses FDA’s compliance policy for these requirements. FDA intends to delay enforcement of these requirements for six months to help ensure that industry has sufficient time to submit facility registration and product listing information.

This guidance is being implemented without prior public comment because the Agency has determined that prior public participation is not feasible or appropriate. 21 CFR 10.115(g)(2). This guidance is being implemented immediately, but it remains subject to comment in accordance with the Agency’s good guidance practices. 21 CFR 10.115(g)(5).

FDA’s guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidance means that something is suggested or recommended, but not required.

Download the Guidance

Related Resources

Submit Comments

Submit Comments Online

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2023-D-1716.

Back to Top